HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024. In addition, Avirmax will have an exhibitor booth #818 to showcase the latest progress and data package. ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy.
Title: Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeysPresenter: Li Ou, Ph.D.Session title: AAV Capsid Engineering: Multilevel Approaches for Enhanced AAV DeliveryPresentation type: Oral PresentationDate and Time: Friday, May 10, 3:45pm - 4:00pm
This presentation focuses on Avirmax's lead candidate ABI-110 for wet AMD and PCV using a proprietary novel capsid AAV2.N54. AAV2.N54 was developed through capsid engineering and showed significantly improved tropism to the macular retina over wildtype serotypes and AAV2.7m8 in mice, rabbits, pigs, and non-human primates. Avirmax Biopharma has completed cGMP manufacturing of ABI-110 using VSafTM  rAAV Production Platform with Sf-rhabdovirus free Sf9 cells and presently prepares regulatory submission for clinical investigations
Avirmax Biopharma has completed cGMP manufacturing of ABI-110 using VSafTM  rAAV Production Platform with Sf-rhabdovirus free Sf9 cells and presently prepares regulatory submission for clinical investigations
Title: Comprehensive Head-to-Head Comparisons Demonstrated Key Advantages of The Sf9 System Over HEK293 in rAAV ManufacturingPresenter: Li Ou, Ph.D.Session title: AAV Vectors - Product Development Manufacturing and Approval ConsiderationsPresentation type: Poster PresentationDate and Time: Friday, May 10, 12:00 pm
This presentation focuses on the systematic comparison between AAV vectors manufactured by the traditional HEK293 plasmid transfection system and the Sf9/baculoviral infection system. As shown in the publication in Molecular Therapy from Avirmax, the Sf9 system has advantages in yields, full capsid ratio, aggregation, purity, and potency over traditional HEK293 systems.
About Avirmax Inc.Avirmax Inc. is a San Francisco-based company specializing in developing rAAV-mediated therapeutics for ocular diseases using its AAV engineering technologies and Sf9-based AAV manufacturing platform. Visit us at avirmax.com for more information.
References
Liu S, Li J, Peraramelli S, Luo N, Chen A, Dai M, Liu F, Yu Y, Leib RD, Li Y, Lin K, Huynh D, Li S, Ou L. Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells. Mol Ther. 2023 Nov 20:S1525-0016(23)00623-8.
Contact
Please contactJune Song, Associate Director for OperationsEmail: [email protected]Tel: +1-510-641-0201
Address
25503 Whitesell StreetHayward 94545 CAUSA
SOURCE Avirmax
Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual...
Li Ou, Ph.D., Vice President of Research at Avirmax Inc., will chair two scientific sessions at the upcoming American Society of Gene and Cell...

Source prnewswire